Corona Remedies

Why is Corona Remedies Ltd falling/rising?

As of 03-Aug, the stock price of Corona Remedies Ltd is rising, currently at 2,105.30, reflecting strong market performance and positive investor sentiment. This increase is supported by record financial results, heightened institutional investor interest, and favorable technical indicators.

As of 03-Aug, the stock price of Corona Remedies Ltd is rising, currently at 2,105.30, with a change of 7.7 (0.37%) upward. This upward movement can be attributed to several factors. Firstly, the stock has recently hit a new 52-week and all-time high of Rs 2,208.05, indicating strong market performance. Additionally, the stock has outperformed its sector by 0.56% today and has shown a consecutive gain over the last two days, with a total increase of 2.04% during this period.<BR><BR>The stock opened with a significant gap up of 3.93% today and reached an intraday high of Rs 2,208.05, reflecting positive investor sentiment. Furthermore, Corona Remedies Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a strong bullish trend.<BR><BR>Institutional investor participation has also increased, with a 7.27% rise in their stake over the previous quarter, indicating confidence from more sophisticated investors in the company's fundamentals. The company reported strong financial results for the quarter ending June 26, achieving record net sales and profits, which further supports the stock's upward trajectory.<BR><BR>Despite a recent decline in delivery volume, which fell by 47.12% against the 5-day average, the overall liquidity remains sufficient for trading. The combination of strong financial performance, positive institutional interest, and technical indicators suggests that the stock's price is rising due to robust market confidence in Corona Remedies Ltd.

Which are the latest news on Corona Remedies?

Should I buy, sell or hold Corona Remedies Ltd?

Are Corona Remedies Ltd latest results good or bad?

Corona Remedies Ltd's latest results show strong profit and revenue growth, with a net profit of ₹45.33 crore and a revenue increase of 20.23% year-on-year. However, the significant decline in operating margins raises concerns about operational efficiency and sustainability moving forward.

The latest results for Corona Remedies Ltd indicate a mixed performance. On the positive side, the company reported a consolidated net profit of ₹45.33 crore for Q4 FY26, which is a significant increase of 43.68% year-on-year and a 9.84% rise quarter-on-quarter. Additionally, revenue grew to ₹353.09 crore, reflecting a year-on-year increase of 20.23% and a sequential growth of 3.12%. <BR><BR>However, there are notable concerns regarding operational efficiency. The operating margin, which declined to 17.56%, represents a sharp drop of 673 basis points from the previous quarter, indicating significant margin compression. This decline is attributed to rising employee costs, which increased substantially and outpaced revenue growth.<BR><BR>Overall, while the company has shown strong profit and revenue growth, the deterioration in margins raises questions about the sustainability of this performance. Investors should monitor how the company addresses these margin pressures in future quarters.

What does Corona Remedies do?

Corona Remedies Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 353 Cr and a net profit of 45 Cr for March 2026, with a market cap of INR 10,856 Cr. Key metrics include a P/E ratio of 53.00 and a return on equity of 26.75%.

Overview:<BR>Corona Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The specific incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 353 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 45 Cr (Quarterly Results - Mar 2026) <BR>Market-cap: INR 10,856 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 53.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.16 <BR>Return on Equity: 26.75% <BR>Price to Book: 14.50 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Corona Remedies?

As of 10th June, Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, with recent net sales of 1,403.18 Cr and a net profit of 185.12 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,403.18 Cr, while the sum of Net Profit for the same period is 185.12 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 606.34 Cr, and Total Assets amount to 929.86 Cr.

Who are the peers of the Corona Remedies?

Corona Remedies' peers include Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, and Blue Jet Health. Most peers show Below Average growth and management risk, with Shilpa Medicare having the highest 1-year return at 15.43%, while Blue Jet Health has the lowest at -47.29%.

Peers: The peers of Corona Remedies are Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer and P & G Health Ltd, while Good management risk is found at Alivus Life, Marksans Pharma, and Blue Jet Health, and Average management risk is noted for Viyash Scientifi and Akums Drugs. Below Average management risk is present at Shilpa Medicare and Strides Pharma. All peers exhibit Below Average growth, except for Akums Drugs, which has Good growth. Capital Structure ratings show Excellent at Alivus Life, Marksans Pharma, Sanofi Consumer, P & G Health Ltd, and Blue Jet Health, while Good is observed at Akums Drugs, and Below Average at Shilpa Medicare, Viyash Scientifi, and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shilpa Medicare at 15.43%, while Blue Jet Health has the lowest at -47.29%. Corona Remedies' 1-year return is not available for comparison. Additionally, Blue Jet Health is the only peer with a negative six-month return.

Has Corona Remedies Ltd declared dividend?

Yes, Corona Remedies Ltd has declared a 100% dividend with an ex-date of June 19, 2026. However, the dividend yield is 0%, and total returns have been mixed, with a 7.52% return in the last 3 months but no returns over longer periods.

Corona Remedies Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 19 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%.<BR><BR>Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Corona Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that there has been no effective return from dividends in recent years. The total returns over various periods show a mixed performance, with a notable return in the last 3 months but no returns in the longer periods.